Clinical trials: Advanced Malignant Solid Tumours
Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer
A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination
The purpose of this study is to learn about the safety (the impact of the study drug on the participant's body), effects of the study drug alone or in combination with bevacizumab or sasanlimab, and to find the best dose.
- Conditions
- Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Urothelial Cancer
- Trial name
- LTbR (NCT06448364)
- Testing
- PF-07329640, sasanlimab, bevacizumab
- Where
- 7 sites in United States, Puerto Rico
- Volunteers
- 4 people
- Sponsor
- Pfizer
Nectin4-positive Advanced Malignant Solid Tumor
Interventional Therapy Sequential With the Fourth-generation CAR-T Targeting Nectin4/FAP for Malignant Solid Tumors
According to the high expression of tumor cell-associated antigen Nectin4 in patients with solid tumors such as non-small cell lung cancer, breast cancer, ovarian cancer, bladder cancer, and pancreatic cancer, and in order to…
- Trial name
- NCT03932565
- Testing
- CAR-T therapy for nectin4-positive malignant solid tumor
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- The Sixth Affiliated Hospital of Wenzhou Medical University
Malignant Neoplasm
A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)
The goal of this study is to learn about the safety of different doses of MK-4700 and if people tolerate them. The study will also measure what happens in a person's body over time when MK-4700 is given alone or with…
- Trial name
- NCT06894771
- Testing
- MK-4700, Pembrolizumab
- Where
- 7 sites in United States, Canada and 1 more
- Volunteers
- 5 people
- Sponsor
- Merck Sharp & Dohme LLC
Tumor, Tumor, Solid
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes
- Conditions
- Tumor, Tumor, Solid, Metastasis, Metastatic Cancer
- Trial name
- NCT05103358
- Testing
- nab-sirolimus
- Where
- 166 sites in United States, Puerto Rico and 1 more
- Volunteers
- 128 people
- Sponsor
- Aadi Bioscience, Inc.
Parent-Child Relations, Cancer
Cancer Parenting Program for the Enhancement of the Quality of Life of Patients With Advanced Cancer and Their Children
This trial examines the usefulness of two educational programs for parents with late-stage cancer who have a 5 - 17 year old child.
- Conditions
- Parent-Child Relations, Cancer, Survivorship, Hematopoietic and Lymphoid System Neoplasm
- Trial name
- EC-PC (NCT05477784)
- Testing
- Group 1: Educational counseling intervention, Group II Active Comparator
- Where
- 2 sites in United States
- Volunteers
- 174 people
- Sponsor
- University of Washington
Malignant Solid Tumors
Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors
Primary Objectives: To determine the maximum tolerated dose (MTD) of SAR125844. To confirm safety profile of SAR125844 when administered as single agent at the MTD.
- Trial name
- SARMET (NCT01391533)
- Testing
- SAR125844
- Where
- 8 sites in United States, France and 2 more
- Volunteers
- 72 people
- Sponsor
- Sanofi
Adult Solid Tumor
Study of LTC004 in Subjects With Advanced Malignant Tumors
This was a multicenter, open, multi-cohort PHASE I study, consisting of 2 phases: Phase Ia (Phase Ia dose escalation) and Phase Ib (Phase Ib multi-cohort expansion).
- Trial name
- NCT05666635
- Testing
- LTC004
- Volunteers
- 368 people
- Sponsor
- Letolab
Cancer
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499733
- Testing
- cyclophosphamide, Cryoablation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
This phase Ib/II trial studies the side effects and best dose of trametinib and navitoclax and how well they work in treating patients with solid tumors that have spread to other places in the body (advanced or metastatic).
- Conditions
- Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Trial name
- NCT02079740
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 96 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Neoplasmas, Solid Tumors
Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors
Treatment of cancer is often more effective when two or more drugs are used together. For example, when gemcitabine, an approved drug, and ON 01910.Na, a new investigational anti-cancer drug, are used together to treat cancer…
- Trial name
- NCT01125891
- Testing
- gemcitabine, ON 01910.Na
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Traws Pharma, Inc.
Malignant Neoplasms, Metastatic Cancer
A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors
Evaluate the safety and tolerability of BPI-421286 in adult subjects with advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with advanced solid tumors.
- Trial name
- NCT05315180
- Testing
- BPI-421286
- Where
- 5 sites in China
- Volunteers
- 80 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma
Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
This phase I/II trial studies the best dose and side effects of peposertib and to see how well it works with avelumab and hypofractionated radiation therapy in treating patients with solid tumors and hepatobiliary malignancies…
- Conditions
- Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma, Locally Advanced Unresectable Gallbladder Carcinoma, Locally Advanced Unresectable Malignant Solid Neoplasm
- Trial name
- NCT04068194
- Testing
- Avelumab, Biopsy Procedure, Biospecimen Collection
- Where
- 46 sites in United States
- Volunteers
- 103 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Solid Tumor
First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors
This study is investigating a new experimental therapy, MP0317, a DARPin® drug candidate targeting fibroblast activation protein (FAP) and CD40.
- Trial name
- NCT05098405
- Testing
- MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q3w regimen), MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q1w regimen)
- Where
- 4 sites in France, Netherlands
- Volunteers
- 46 people
- Sponsor
- Molecular Partners AG
Advanced Cancer
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
The purpose of this study is to demonstrate the safety and preliminary activity with triple combinations of relatlimab in combination with nivolumab and BMS-986205, or in combination with nivolumab and ipilimumab in…
- Trial name
- NCT03459222
- Testing
- Relatlimab, Nivolumab, BMS-986205
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 229 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumor, Neoplasms
A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerance, Dose-Limiting Toxicity (DLT), Maximum tolerated dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of ES102 (OX40 agonist) in combination with JS001 (anti-PD-1…
- Conditions
- Solid Tumor, Neoplasms, Malignant Tumor
- Trial name
- NCT04991506
- Testing
- ES102, JS001
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Elpiscience Biopharma, Ltd.
Advanced Malignant Solid Tumors
A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors
The objective of this study is to evaluate the safety, tolerability and PK profile of HMPL-415S1 and determine MTD and/or RP2D in patients with advanced malignant solid tumor.
- Trial name
- NCT05886374
- Testing
- HMPL-415S1
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Hutchmed
Advanced Malignant Solid Tumors
Using Neoantigen Peptide Vaccine/neoantigen-based DC to Treat Advanced Malignant Solid Tumors
In this study, the investigators provide a personalized tumor neoantigen peptide vaccine/neoantigen-based DC treatment to patients with advanced malignant solid tumors.
- Trial name
- NCT05749627
- Testing
- Neoantigen peptide vaccine, Neoantigen-based DC immune preparation
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Nanchang University
Advanced Solid Tumor
JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors
This study is an open-label, multicenter, first-in-human, Phase I/II (dose escalation and dose expansion) study to evaluate the safety, tolerability, PK, immunogenicity and efficacy of JSKN033 in patients with advanced…
- Trial name
- NCT06226766
- Testing
- JSKN033 Injection
- Where
- Australia
- Volunteers
- 11 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Neoplasm Malignant
Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors
Primary Objective: To evaluate tolerability and safety of SAR408701 when administered as a single agent according to the investigational medicinal product (IMP) related dose limiting toxicities (DLTs) to determine the recommended…
- Trial name
- NCT03324113
- Testing
- SAR408701, dexamethasone, naphazoline
- Where
- 3 sites in Japan
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Sanofi
Advanced Malignant Solid Neoplasm, Anal Carcinoma
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of nivolumab when given with ipilimumab in treating patients with human immunodeficiency virus (HIV) associated classical Hodgkin lymphoma that has returned after a period…
- Conditions
- Advanced Malignant Solid Neoplasm, Anal Carcinoma, HIV Infection, Kaposi Sarcoma
- Trial name
- NCT02408861
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography
- Where
- 34 sites in United States, Australia
- Volunteers
- 79 people
- Sponsor
- National Cancer Institute (NCI)